Matthew W. VanBrocklin, PhD

Research Interests

  • Molecular Targets
  • Melanoma
  • Carcinoma, Non-Small-Cell Lung

Labs

Lab Website

Languages

  • English

Academic Information

  • Departments: Surgery - Associate Professor
  • Divisions: General Surgery
  • Cancer Center Programs: Cell Response & Regulation

Academic Office Information

  • 801-213-4236
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 5280.1
    Salt Lake City, UT 84112

Academic Bio

Matthew VanBrocklin, PhD, is an assistant professor in the Department of Surgery at the University of Utah Hospital, an investigator at the Huntsman Cancer Institute (HCI), and a member of the Cell Response and Regulation program.

At HCI, VanBrocklin researches novel therapeutic targets and signal transduction pathways (networks inside a cell that transmit outside signals to influence cellular responses) that are important for increasing survival in melanoma, non-small cell lung cancer (NSCLC), and brain tumors. He also aims to develop novel small peptide-based agents directed at therapeutic targets that are currently considered "undruggable".

Before joining HCI, VanBrocklin was a researcher at the Nevada Cancer Institute, where he completed a postdoctoral fellowship, established his own lab, and became a member of the Drug Development Division. He received a PhD in biomedical science from Western Michigan University in Kalamazoo, Michigan.

Education History

Type School Degree
Postdoctoral Fellowship Nevada Cancer Institute
Postdoctoral Fellow
Doctoral Training Western Michigan University
Biomedical Science
Ph.D.
Graduate Training Mayo Graduate School
Immunology
M.S.
Undergraduate Western Michigan University
Biomedical Science/Chemistry
B.S.
Other Training Bay de Noc Community College

Selected Publications

Journal Article

  1. Kumar D, Rahman H, Tyagi E, Liu T, Li C, Lu R, Lum D, Holmen SL, Maschek JA, Cox JE, VanBrocklin MW, Grossman D (2018 Jul 18). Aspirin suppresses PGE2 and activates AMP kinase to inhibit melanoma cell motility, pigmentation and selective tumor growth in vivo.LID - canprevres.0087.2018 [pii]LID - 10.1158/1940-6207.CAPR-18-0087 [doi]. (Epub ahead of print) Cancer Prev Res (Phila).
  2. Philip B, Yu DX, Silvis MR, Shin CH, Robinson JP, Robinson GL, Welker AE, Angel SN, Tripp SR, Sonnen JA, VanBrocklin MW, Gibbons RJ, Looper RE, Colman H, Holmen SL (2018 May 1). Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep, 23(5), 1553-1564.
  3. Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW (2017 Dec). Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. Melanoma Res, 27(6), 545-557.
  4. Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT (2017 Nov). A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. Clin Breast Cancer, 17(7), 503-509.
  5. Shin CH, Robinson JP, Sonnen JA, Welker AE, Yu DX, VanBrocklin MW, Holmen SL (2017 Aug 10). HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss. Oncogene, 36(32), 4610-4618.
  6. Yang H, Kircher DA, Kim KH, Grossmann AH, VanBrocklin MW, Holmen SL, Robinson JP (2017 Jul 6). Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma. Oncogene, 36(27), 3842-3851.
  7. Cohen AL, Ray A, Van Brocklin MW, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT (). A Phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget.
  8. Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT (2016 Sep 27). A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. Oncotarget, 7(39), 64390-64399.
  9. Robinson GL, Philip B, Guthrie MR, Cox JE, Robinson JP, VanBrocklin MW, Holmen SL (2016 May). In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using Bimolecular Fluorescence Complementation. Cancer Res Front, 2(2), 311-329.
  10. Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, Davies MA, Grossmann AH, VanBrocklin MW, McMahon M, Holmen SL (). AKT1 Activation Promotes Development of Melanoma Metastases. Cell Reports. Cell Rep, 13(5), 898-905.
  11. Melder DC, Pike GM, VanBrocklin MW, Federspiel MJ (2015 Feb). Model of the TVA receptor determinants required for efficient infection by subgroup A avian sarcoma and leukosis viruses. J Virol, 89(4), 2136-48.
  12. Robinson GL, Robinson JP, Lastwika KJ, Holmen SL, Vanbrocklin MW (2013 Nov). Akt signaling accelerates tumor recurrence following ras inhibition in the context of ink4a/arf loss. Genes Cancer, 4(11-12), 476-85.
  13. Vanbrocklin MW, Robinson JP, Lastwika KJ, McKinney AJ, Gach HM, Holmen SL (2012 Jan). Ink4a/Arf loss promotes tumor recurrence following Ras inhibition. Neuro Oncol, 14(1), 34-42.
  14. Robinson JP, Vanbrocklin MW, Lastwika KJ, McKinney AJ, Brandner S, Holmen SL (2011 Mar 17). Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene, 30(11), 1341-50.
  15. Robinson JP, Vanbrocklin MW, McKinney AJ, Gach HM, Holmen SL (2011). Akt signaling is required for glioblastoma maintenance in vivo. Am J Cancer Res, 1(2), 155-167.
  16. VanBrocklin MW, Robinson JP, Lastwika KJ, Khoury JD, Holmen SL (2010 Aug). Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice. Pigment Cell Melanoma Res, 23(4), 531-41.
  17. Melnik MK, Webb CP, Richardson PJ, Luttenton CR, Campbell AD, Monroe TJ, ORourke TJ, Yost KJ, Szczepanek CM, Bassett MR, Truszkowski KJ, Stein P, Van Brocklin MW, Davis AT, Bedolla G, Vande Woude GF, Koo HM (2010 Aug). Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer. Mol Cancer Ther, 9(8), 2423-9.
  18. Robinson JP, VanBrocklin MW, Guilbeault AR, Signorelli DL, Brandner S, Holmen SL (2010 Jan 21). Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene, 29(3), 335-44.
  19. Vanbrocklin MW, Robinson JP, Whitwam T, Guilbeault AR, Koeman J, Swiatek PJ, Vande Woude GF, Khoury JD, Holmen SL (2009 Aug). Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell Melanoma Res, 22(4), 454-60.
  20. VanBrocklin MW, Verhaegen M, Soengas MS, Holmen SL (2009 Mar 1). Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res, 69(5), 1985-94.
  21. Chen M, Granger AJ, Vanbrocklin MW, Payne WS, Hunt H, Zhang H, Dodgson JB, Holmen SL (2007 Sep 1). Inhibition of avian leukosis virus replication by vector-based RNA interference. Virology, 365(2), 464-72.
  22. Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, Koo HM, Holmen SL (2007 Jul 5). Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene, 26(31), 4563-70.
  23. Verhaegen M, Bauer JA, Martin de la Vega C, Wang G, Wolter KG, Brenner JC, Nikolovska-Coleska Z, Bengtson A, Nair R, Elder JT, Van Brocklin M, Carey TE, Bradford CR, Wang S, Soengas MS (2006 Dec 1). A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res, 66(23), 11348-59.
  24. Orchekowski R, Hamelinck D, Li L, Gliwa E, vanBrocklin M, Marrero JA, Vande Woude GF, Feng Z, Brand R, Haab BB (2005 Dec 1). Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res, 65(23), 11193-202.
  25. Wang PF, Kong D, Van Brocklin MW, Peng J, Zhang C, Potter SJ, Gao X, Teh BT, Zhang N, Williams BO, Holmen SL (). Simplified method for the construction of gene targeting vectors for conditional gene inactivation in mice. Transgenics, 4(3), 215-218.
  26. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM (2003 Dec 1). Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res, 63(23), 8330-7.
  27. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Vande Woude GF (2002 Mar 5). Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A, 99(5), 3052-7.
  28. VanBrocklin M, Federspiel MJ (2000 Feb 1). Capsid-targeted viral inactivation can eliminate the production of infectious murine leukemia virus in vitro. Virology, 267(1), 111-23.
  29. Wilson CA, Wong S, VanBrocklin M, Federspiel MJ (2000 Jan). Extended analysis of the in vitro tropism of porcine endogenous retrovirus. J Virol, 74(1), 49-56.
  30. Schaefer-Klein J, Givol I, Barsov EV, Whitcomb JM, VanBrocklin M, Foster DN, Federspiel MJ, Hughes SH (1998 Sep 1). The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology, 248(2), 305-11.
  31. VanBrocklin M, Ferris AL, Hughes SH, Federspiel MJ (1997 Apr). Expression of a murine leukemia virus Gag-Escherichia coli RNase HI fusion polyprotein significantly inhibits virus spread. J Virol, 71(4), 3312-8.
  32. Holmen SL, Vanbrocklin MW, Eversole RR, Stapleton SR, Ginsberg LC (1995 May). Efficient lipid-mediated transfection of DNA into primary rat hepatocytes. In Vitro Cell Dev Biol Anim, 31(5), 347-51.

Video